论文部分内容阅读
尼洛替尼(nilotinib hydrochloride monohydrate)是由诺华制药公司(Novartis Pharms.Inc)开发的一种口服酪氨酸激酶抑制剂,商品名Tasigna。该药为口服胶囊剂,于2007年10月获美国FDA批准上市,是用于治疗慢性粒细胞白血病(CML)的二线药物。尼洛替尼的化学名称:4-甲基-N-[3-(4-甲
Nilotinib hydrochloride monohydrate is an oral tyrosine kinase inhibitor developed by Novartis Pharms. Inc. under the trade name Tasigna. The drug, an oral capsule, was approved by the US FDA in October 2007 and is a second-line drug for the treatment of chronic myeloid leukemia (CML). Nilotinib’s chemical name: 4-methyl-N- [3- (4-methyl